TY - JOUR
T1 - Practicality, validity and responsiveness of using the proxy version of the Child Health Utility–9 Dimensions with children aged 2 to 5 years
AU - Sach, Tracey H.
AU - Williams, Hywel C.
AU - BEEP Study Team
AU - Allen, Hilary
AU - Boyle, Robert
AU - Kelleher, Maeve
AU - Brown, Sara
AU - Cork, Mike
AU - Flohr, Carsten
AU - Jay, Nicola
AU - Lartey, Stella
AU - Davies, Charlotte
AU - Lawton, Sandra
AU - Perkin, Michael
AU - Ridd, Matthew
AU - Sach, Tracey H.
AU - Brooks, Joanne
AU - Haines, Rachel
AU - Mitchell, Eleanor
AU - Montgomery, Alan
AU - Swinden, Richard
AU - Tarr, Stella
AU - Wyatt, Laura
AU - Thomas, Kim
AU - Williams, Hywel
AU - Chalmers, Joanne
AU - Davies-Jones, Susan
N1 - Funding Information: This study presents independent research funded by the National Institute for Health and Care Research (NIHR) under its Health Technology Assessment program (12/67/12). Research nurse support was provided by the NIHR Clinical Research Networks. The trial was developed with and supported by the UK Dermatology Clinical Trials Network. The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health and Social Care.
This trial was registered prospectively with the ISRCTN registry (ISRCTN21528841). The study was sponsored by the University of Nottingham , coordinated by the Nottingham Clinical Trials Unit.
PY - 2024/12
Y1 - 2024/12
N2 - Objectives: This study aimed to assess the practicality, validity, and responsiveness of the proxy Child Health Utility–9 Dimensions (CHU9D) in children aged 2 to 5 years. Methods: We used data from the Barrier Enhancement for Eczema Prevention trial, a UK randomized controlled trial testing whether daily emollients in infancy could prevent eczema in high-risk infants. The main parent/carer completed the proxy CHU9D using developers’ additional guidance for completion in those younger than 5 years and the Patient-Oriented Eczema Measure (POEM) at ages 2, 3, 4, and 5 years. Practicality was assessed by completion rates. Construct validity assessed whether CHU9D could discriminate between those with/without eczema and between eczema severity levels on POEM. Responsiveness was determined by ability to discriminate between 3 groups: (1) those whose POEM score deteriorated ≥3 points, (2) those whose change was not clinically important (−2.9 to 2.9 points), and (3) those whose POEM score improved ≥3 points. Analysis was conducted in Stata 17. Results: Of 1394 children participating in the Barrier Enhancement for Eczema Prevention trial, study questionnaires were completed by 1212 (87%), 981 (70%), 990 (71%), and 976 (70%) at 2, 3, 4, and 5 years. Of these the CHU9D was completed by 1066 (88.0%), 685 (69.8%), 925 (93.4%), and 923 (94.6%), respectively. Mean utility at all time points was approximately 0.934 (range 0.443-1). For construct validity, very small differences in the CHU9D between known groups were observed (P < .01). A total of 801 participants had responsiveness data: 13% deteriorated, 72% had nonclinically important change, and 15% improved. Mean utility change (standardized response mean) for these groups was −0.0198 (0.21), 0.0041 (0.05), and 0.0175 (0.21) showing small change and small responsiveness. Conclusions: Proxy CHU9D in 2- to 5-year-old children shows potential but further research is needed.
AB - Objectives: This study aimed to assess the practicality, validity, and responsiveness of the proxy Child Health Utility–9 Dimensions (CHU9D) in children aged 2 to 5 years. Methods: We used data from the Barrier Enhancement for Eczema Prevention trial, a UK randomized controlled trial testing whether daily emollients in infancy could prevent eczema in high-risk infants. The main parent/carer completed the proxy CHU9D using developers’ additional guidance for completion in those younger than 5 years and the Patient-Oriented Eczema Measure (POEM) at ages 2, 3, 4, and 5 years. Practicality was assessed by completion rates. Construct validity assessed whether CHU9D could discriminate between those with/without eczema and between eczema severity levels on POEM. Responsiveness was determined by ability to discriminate between 3 groups: (1) those whose POEM score deteriorated ≥3 points, (2) those whose change was not clinically important (−2.9 to 2.9 points), and (3) those whose POEM score improved ≥3 points. Analysis was conducted in Stata 17. Results: Of 1394 children participating in the Barrier Enhancement for Eczema Prevention trial, study questionnaires were completed by 1212 (87%), 981 (70%), 990 (71%), and 976 (70%) at 2, 3, 4, and 5 years. Of these the CHU9D was completed by 1066 (88.0%), 685 (69.8%), 925 (93.4%), and 923 (94.6%), respectively. Mean utility at all time points was approximately 0.934 (range 0.443-1). For construct validity, very small differences in the CHU9D between known groups were observed (P < .01). A total of 801 participants had responsiveness data: 13% deteriorated, 72% had nonclinically important change, and 15% improved. Mean utility change (standardized response mean) for these groups was −0.0198 (0.21), 0.0041 (0.05), and 0.0175 (0.21) showing small change and small responsiveness. Conclusions: Proxy CHU9D in 2- to 5-year-old children shows potential but further research is needed.
KW - CHU9D
KW - pediatric
KW - proxy
KW - psychometric properties
UR - http://www.scopus.com/inward/record.url?scp=85208022168&partnerID=8YFLogxK
U2 - 10.1016/j.jval.2024.08.010
DO - 10.1016/j.jval.2024.08.010
M3 - Article
SN - 1098-3015
VL - 27
SP - 1771
EP - 1778
JO - Value in Health
JF - Value in Health
IS - 12
ER -